Letybo Disease Interactions
There are 3 disease interactions with Letybo (letibotulinumtoxinA).
Botulinum toxin products (applies to Letybo) dysphagia/respiratory/neuromuscular disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Myasthenia Gravis, Pulmonary Impairment
Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA, letibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise. Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Patients treated with botulinum toxin may require immediate medical attention should they develop these complications. Caution is advised.
References
- "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc
- "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc
- (2022) "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals
- (2022) "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc., 1
- (2024) "Product Information. Letybo (letibotulinumtoxinA)." Hugel Aesthetics
Botulinum toxin products (applies to Letybo) infection
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, letibotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).
References
- "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc
- "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc
- (2022) "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals
- (2022) "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc., 1
- (2024) "Product Information. Letybo (letibotulinumtoxinA)." Hugel Aesthetics
LetibotulinumtoxinA (applies to Letybo) cardiovascular disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: History - Myocardial Infarction
Use caution when administering letibotulinumtoxinA to patients with preexisting cardiovascular conditions. Adverse cardiovascular outcomes (some fatal), including arrhythmia and myocardial infarction, have been reported following administration of botulinum toxin products. In some cases, patients had risk factors including preexisting-existing cardiovascular disease.
References
- (2024) "Product Information. Letybo (letibotulinumtoxinA)." Hugel Aesthetics
Letybo drug interactions
There are 119 drug interactions with Letybo (letibotulinumtoxinA).
More about Letybo (letibotulinumtoxinA)
- Letybo consumer information
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- FDA approval history
- Drug class: skeletal muscle relaxants
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.